By admin 
Moving beyond just LDL, or “bad,” cholesterol, and just statins, the updated recommendations take a more sweeping approach for when and how to prevent and treat cardiovascular diseases caused by the hardening and narrowing of arteries. For decades, the medical establishment focused primarily on 10-year risk windows for middle-aged and older adults. However, the 2026 guidelines recognize that the seeds of heart disease are often sown in early adulthood. By focusing on a 30-year risk horizon and beginning the conversation at age 30, physicians hope to prevent the "silent" buildup of plaque that eventually leads to myocardial infarctions and ischemic strokes. This "lower for longer" philosophy suggests that maintaining optimal lipid levels early in life provides a compounding benefit, much like financial interest, significantly reducing the total burden of disease in later years.
Changing behavior or adding medication is encouraged when LDL, or “bad,” cholesterol numbers hit 160 mg/dL or higher in people without heart disease, beginning in young adulthood at age 30. That approach can start with healthier lifestyle habits and move on to add statins or other drugs if there’s a strong family history of early heart disease or a risk assessment pointing to elevated 30-year odds of developing cardiovascular disease. When diet and exercise don’t lower lipids enough, imaging calcium in coronary arteries is an option to assess some people’s risk of heart attack or stroke before deciding on medication. This nuanced approach recognizes that while lifestyle remains the cornerstone of health, genetic predispositions often require pharmacological assistance. The guidelines emphasize that for some high-risk individuals, even a perfect diet cannot overcome the liver’s overproduction of cholesterol.
“These guidelines represent an important shift toward identifying higher‑risk individuals earlier and treating them more effectively,” Gregg Fonarow, a cardiologist and professor of cardiovascular medicine and science at UCLA, told STAT via email. He was not involved in drafting the guidelines but emphasized the public health urgency behind them. “It is deeply concerning that so many cardiovascular events occur each year that could have been prevented with earlier identification and treatment of risk. These new guidelines provide a clearer, more contemporary roadmap that can help reduce this burden.” Fonarow’s perspective highlights a frustration shared by many in the field: the medical community has long possessed the tools to lower cholesterol, yet heart disease rates remain stubbornly high, partly due to delayed intervention.
The new guidelines from the American College of Cardiology, the American Heart Association, and nine other medical organizations are based on a risk calculator released in November 2024 that was hailed as more reliable than previous equations drawn from less comprehensive evidence. The new calculator, known as the PREVENT (Predicting Risk of Cardiovascular Disease EVENTs) equations, represents a significant technological leap. Unlike the previous Pooled Cohort Equations (PCE), which were criticized for overestimating risk in some populations and underestimating it in others, PREVENT utilizes more diverse data sets. Crucially, the new equations remove race as a biological variable—a move praised by health equity advocates—and instead incorporate measures of kidney health and metabolic function, which are more direct physiological indicators of cardiovascular strain.
The new calculator had raised concern over the past 16 months. If used in tandem with existing thresholds for treatment, it turned out, far fewer people would qualify for a statin. Many people already don’t take their prescribed statins, so diminishing the number eligible by as much as 40% was feared as a failure of prevention. This "statins gap" created a paradox for the writing committee: how to use a more accurate tool without inadvertently leaving millions of vulnerable patients unprotected. The solution found in the 2026 guidelines was to recalibrate the thresholds for action. By lowering the bar for what constitutes "high risk," the organizations ensured that those who truly need medication are still identified, while those at truly low risk are spared unnecessary prescriptions.
Timothy Anderson, a primary care physician and assistant professor of medicine at the University of Pittsburgh Medical Center, was one of the researchers raising concerns about matching PREVENT to risk thresholds. Also a member of the 2026 guidelines writing committee, he praised the PREVENT equations as a well-validated risk estimation tool with updated accuracy. “The full rationale is really this idea of trying to balance the potential benefit of lipid-lowering therapies like statins against the potential risks,” he told STAT. “A real focus of the guidelines is identifying and treating high cholesterol earlier on, out of the hypothesis that long-term exposure to high cholesterol may have greater risks than short-term exposure.” This concept of "area under the curve" for LDL exposure is central to the new logic: it is not just how high your cholesterol is today, but how many years your arteries have been bathed in it.
Earlier intervention means looking at 10-year risk estimates as well as 30-year predictions. The new PREVENT equations classify 10-year cardiovascular disease risk from plaque-lined arteries as low (under 3%), borderline (3% to 5%), intermediate (5% to 10%), and high (10% or higher). These risk categories form the foundation for treatment decisions, from starting statin therapy to determining intensity of lipid lowering. A composite of other factors, including family history, inflammatory disease, diabetes, kidney disease, cancer, HIV, and certain reproductive conditions, influence how risk is calculated. For example, a patient with a "borderline" numerical score might be pushed into the "intermediate" or "high" treatment category if they also suffer from a chronic inflammatory condition like rheumatoid arthritis, which is known to accelerate arterial damage.
Treatment is now recommended at much lower LDL levels for people, depending on their current health. To prevent a first heart attack or stroke, LDL should be under 100 mg/dL for those at borderline or intermediate risk and under 70 mg/dL in those at high risk. But in people who already have fatty buildup in their blood vessels deemed at very high risk of heart attack, stroke, or peripheral artery diseases, the LDL goal drops to under 55 mg/dL. This "55 is the new 70" mantra reflects data from recent clinical trials showing that even among those with already low cholesterol, further reductions lead to fewer cardiac events.
Roger Blumenthal, chair of the guideline writing committee and director of the Johns Hopkins Ciccarone Center for the Prevention of Heart Disease, compared lipid-lowering drugs to medications to reduce blood pressure. The longer both are in control, the better, yielding much stronger protection against future heart attack and stroke risk. That argues for looking at 10-year risk estimates as early as age 30. “The PREVENT score gives us a good educated guess, but keep in mind these numbers are pretty low when we talk about intermediate risk being a 5% to 10% 10-year risk,” he told STAT. “Some patients have already said, ‘Well, Dr. Blumenthal, that’s a 1 in 20 chance that I’ll get a cardiovascular event.’ That’s very true. But I tell them that if you have other factors that support earlier treatment, that may sway us to being more aggressive in your management.”
Beyond family history, those risk enhancers include being overweight or obese, diabetes, and chronic kidney disease, as well as chronic inflammatory conditions such as lupus or rheumatoid arthritis. Having South Asian or Filipino ancestry also means a higher risk for developing atherosclerosis, a recognition of the ethnic disparities in cardiovascular outcomes that previous guidelines often overlooked. For women, the guidelines introduce critical nuances regarding reproductive health. While women tend to develop atherosclerotic disease about 10 years later than men, that delay is erased if they experienced early premature menopause, preeclampsia, gestational diabetes, or hypertension during pregnancy. “If they have one of these reproductive risk markers of increased cardiovascular risk, then that, I think, will lead to more clinicians and patients thinking about being much more aggressive in their lifestyle habits and, if necessary, using a medicine to lower their cholesterol,” Blumenthal said.
Markers in the blood other than cholesterol have drawn more attention in recent years. Lipoprotein(a), apolipoprotein B (ApoB), and high-sensitivity C-reactive protein (hs-CRP) are considered important in establishing someone’s risk. Lp(a), shaped by genetics and shared by about 1 in 5 Americans, should be measured once over a lifetime, the guidelines say. Having levels 50 mg/dL or higher is associated with about a 40% increased long-term risk of heart attack or stroke. Lifestyle changes don’t alter Lp(a) levels, but high Lp(a) combined with high LDL should signal a conversation about lowering LDL. Blumenthal said Lp(a) could be a tiebreaker in someone on the cusp for treatment. Furthermore, in people with cardiovascular-kidney-metabolic (CKM) syndrome, type 2 diabetes, high triglycerides, or known cardiovascular disease who have reached their cholesterol goals, ApoB may be a more accurate risk marker for future cardiovascular disease than LDL cholesterol, as it measures the total number of atherogenic particles in the bloodstream.
Throughout the 123 pages of guidelines, the emphasis is not just on statins or LDL cholesterol. Recognizing that all who might benefit don’t take statins, the authors still accord them a place in early treatment. The workhorses of cardiovascular disease prevention have long been sold at about $40 a year. Their introduction in the 1980s has been compared to today’s obesity drugs for the scale of their impact in preventing heart attacks, strokes, and peripheral artery disease. However, statins have become a victim of their own success, often viewed with skepticism by a public wary of lifelong medication. There are side effects, and fear of them. Some people feel muscle pain and others see their blood sugar rise enough to develop type 2 diabetes, an absolute risk increase that studies estimate ranges from 0.1% to 0.5%. Blumenthal noted that while these risks are real, 95% or more of patients have no difficulties on the drug, and the cardiovascular benefits usually far outweigh the metabolic risks.
Jeremy Sussman, a primary care physician at the VA Ann Arbor Healthcare System who was not involved in drafting the guidelines, believes statins are very valuable medicines but is concerned about patients who might think taking a statin would be too aggressive. While their chances of developing muscle pain or diabetes are small, their reduced odds of having a heart attack or stroke may also appear small at first, falling only gradually over time. “For many of us, that’s worth it since a heart attack can be a terrible thing,” he said via email, “but it’s worth recognizing that we are encouraging a huge amount of statin use that will only benefit over a very long time period.”
Sussman also raised a critical point regarding the implementation of these guidelines: the lack of representation from primary care physicians in the drafting process. He argued that the guidelines are insufficiently patient-centered, which is particularly problematic given that a large percentage of patients stop taking cholesterol-lowering medications within two years. “The most difficult questions in dyslipidemia treatment are rarely if or when a patient has high enough risk or cholesterol level. It’s trying to understand the patient’s values and how doctors and patients together can decide if a patient should overcome their dislike of medicines to start a pill today for a goal of preventing a heart attack in 20 years,” he said. He suggested that while the guidelines acknowledge these issues, they offer little practical advice on how to conduct these "shared decision-making" conversations in a 15-minute primary care visit.
Statins aren’t the only drugs for cholesterol control. They can be taken with other, more powerful drugs if lipids stay high. In the mix are PCSK9 inhibitors, drugs that block a protein to shrink LDL cholesterol. In an editorial published along with the guidelines in JACC and Circulation, Blumenthal described a trial of a PSCK9 inhibitor in detail. The data about using the drug in people before a first heart attack were presented at the AHA’s scientific session in November 2025, too late for the guidelines but a harbinger of research to come. The guidelines will be updated annually to provide resources for physicians. “With PCSK9 inhibitors that had short-term follow-up of about two to three years, there was about a 15% to 20% relative risk reduction on top of statin therapy,” Blumenthal said. However, he noted the economic reality: “Statins are so much more economically feasible than a PCSK9 inhibitor and insurance companies would much rather pay for a generic statin than a medication that might cost the patient $5,000 a year.”
In addition to blood tests, there is a test called a coronary artery calcium (CAC) scan to help with decisions about taking a statin. When someone’s risk is uncertain, these CT scans can reveal actual calcium and plaque buildup in artery walls—providing a "look inside" the pipes. The tests are recommended for men age 40 and up and women age 45 and up who are living with borderline or intermediate 10-year risk. This expands on the 2018 guidelines, which suggested them primarily for those at intermediate risk. A "zero" score on a CAC scan can sometimes allow a patient to delay statin therapy, while a high score can be the motivation a patient needs to commit to lifestyle changes or medication.
In Blumenthal’s view, there are now many ways to identify a person at higher risk. The science of prediction has matured; the challenge now lies in the art of motivation. “The hardest thing really is to motivate people to improve their lifestyle habits,” Blumenthal said. “But it’s also hard many times to get people to understand that we have such a multitude of great data about lower is better for longer. If we can motivate people to keep striving to improve their lifestyle habits earlier, then there’d be less of a need for medication and less of the need for dealing with all these acute cardiac events that unfortunately plague so many people in the United States and worldwide.” Ultimately, these 2026 guidelines serve as a call to action for both doctors and patients to treat heart health as a lifelong marathon rather than a sprint that begins in middle age.